Shah 2002.

Methods	Randomised, double‐blind, placebo‐controlled single centre study
Participants	62 patients (34 alfuzosin, 28 placebo), mean age 68.6 years
Interventions	A (34): Alfuzosin SR 5 mg twice daily versus B (28): Placebo, TWOC after minimum of three doses or 36 hours after admission
Outcomes	TWOC success rates: A 17/34, B 16/28 Need for further TURP (phase 2)
Notes	Phase 2 of study; all patients with successful TWOC were given Alfuzosin SR 5 mg twice daily and followed up at 1 year and 2 years.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'...double blind, placebo controlled study...' 'Patients were randomised to receive ...'
Allocation concealment (selection bias)	Unclear risk	Not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data
Selective reporting (reporting bias)	Unclear risk	All the outcomes as detailed in the method section of the trial were reported in the result section. Some outcomes which are considered important from patients’ perspective were not reported. Without the protocol it was difficult to judge whether or not these outcomes were included in the protocol and not reported in the report.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not specified
Other bias	High risk	Funding obtained from Lorex Synthelabo Pharma.